Alexis Meredith, MD
Pulmonary Disease · North Kansas City, MONPI 1215004478
Payments from drug & device makers
Across 288 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$733
- Boehringer Ingelheim$346
- Mylan Specialty L.p.$265
- AbbVie$239
- Merck$226
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,332100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $1,125 |
| GSK | 43 | $733 |
| Boehringer Ingelheim | 18 | $346 |
| Mylan Specialty L.p. | 15 | $265 |
| AbbVie(2 entities) | 12 | $239 |
| Merck | 12 | $226 |
| Grifols USA, LLC | 11 | $223 |
| Regeneron Healthcare Solutions, Inc. | 7 | $209 |
| Genentech USA, Inc. | 12 | $197 |
| Jazz Pharmaceuticals Inc. | 9 | $178 |
| Harmony Biosciences LLC | 7 | $152 |
| Sanofi | 8 | $150 |
| Insmed, Inc. | 8 | $143 |
| Axsome Therapeutics, Inc. | 6 | $134 |
| Advanced Respiratory, Inc | 6 | $110 |
| Electromed, Inc. | 7 | $109 |
| Viatris Specialty LLC | 4 | $83 |
| Novartis | 4 | $75 |
| Actelion Pharmaceuticals US, Inc. | 3 | $67 |
| Baxter Healthcare | 3 | $67 |
| Philips North America LLC | 3 | $59 |
| Amgen | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 4 | $52 |
| United Therapeutics Corporation | 2 | $48 |
| Melinta Therapeutics, LLC | 3 | $42 |
| Optinose US, Inc. | 1 | $28 |
| Resmed Corp | 1 | $26 |
| ZOLL Respicardia, Inc. | 1 | $26 |
| Penumbra, Inc. | 1 | $25 |
| Pfizer | 1 | $23 |
| Shire North American Group Inc | 2 | $22 |
| Eisai Inc. | 1 | $22 |
| Verona Pharma, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Pulmonx Corporation | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Circassia Inc. | 1 | $13 |
| Veran Medical Technologies, Inc. | 1 | $7 |
How this compares
$5,350 in reported general payments places this provider in the 60th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $460,832 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 405 | $398,875 |
| Breo ElliptaFluticasone/Vilanterol | 278 | $145,703 |
| FasenraBenralizumab | 13 | $74,424 |
| Spiriva RespimatTiotropium Bromide | 44 | $37,780 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $34,072 |
| XolairOmalizumab | 13 | $32,892 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $31,384 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $31,169 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 61 | $16,660 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $12,252 |
| Arnuity ElliptaFluticasone Furoate | 45 | $12,191 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 77 | $11,683 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 325 | $11,645 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 35 | $9,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy, Arnuity Ellipta | $733 | $604,598833 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $346 | $529,996125 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort | $1,125 | $120,74797 claims |
| PfizerAbrysvo | $23 | $4,62316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in North Kansas City
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
- Alexander ChenSaint Louis$951K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.